- Home
- CBRL vs VRDN Comparison
CBRL vs VRDN Comparison
Compare CBRL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- VRDN
- Stock Information
- Founded
- CBRL 1969
- VRDN 2006
- Country
- CBRL United States
- VRDN United States
- Employees
- CBRL N/A
- VRDN N/A
- Industry
- CBRL Restaurants
- VRDN Medical Specialities
- Sector
- CBRL Consumer Discretionary
- VRDN Health Care
- Exchange
- CBRL Nasdaq
- VRDN Nasdaq
- Market Cap
- CBRL 1.3B
- VRDN 1.5B
- IPO Year
- CBRL N/A
- VRDN N/A
- Fundamental
- Price
- CBRL $60.12
- VRDN $18.44
- Analyst Decision
- CBRL Hold
- VRDN Strong Buy
- Analyst Count
- CBRL 8
- VRDN 11
- Target Price
- CBRL $55.14
- VRDN $38.80
- AVG Volume (30 Days)
- CBRL 1.6M
- VRDN 847.0K
- Earning Date
- CBRL 09-18-2025
- VRDN 08-06-2025
- Dividend Yield
- CBRL 1.66%
- VRDN N/A
- EPS Growth
- CBRL N/A
- VRDN N/A
- EPS
- CBRL 2.58
- VRDN N/A
- Revenue
- CBRL $3,510,062,000.00
- VRDN $305,000.00
- Revenue This Year
- CBRL $1.97
- VRDN N/A
- Revenue Next Year
- CBRL $1.67
- VRDN $35,092.81
- P/E Ratio
- CBRL $23.30
- VRDN N/A
- Revenue Growth
- CBRL 2.84
- VRDN 5.90
- 52 Week Low
- CBRL $33.86
- VRDN $9.90
- 52 Week High
- CBRL $71.93
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- CBRL 54.20
- VRDN 56.43
- Support Level
- CBRL $53.15
- VRDN $18.22
- Resistance Level
- CBRL $63.15
- VRDN $19.73
- Average True Range (ATR)
- CBRL 2.87
- VRDN 0.98
- MACD
- CBRL 0.32
- VRDN -0.01
- Stochastic Oscillator
- CBRL 85.38
- VRDN 65.23
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).